Thalidomide drug may fight blood vessel disorder

	Tweet

Thalidomide, a drug that caused birth defects when it was launched as a morning sickness pill half a century ago, may be useful for treating a hereditary condition that affects blood vessels, scientists said on Sunday.

In a study in the journal Nature Medicine, French researchers found giving thalidomide to patients with a disorder called hereditary hemorrhagic telangiectasia (HHT) reduced the severity and frequency of nosebleeds, one of the main symptoms.

Franck Lebrin, who led the study with colleagues from the National Institute for Health and Medical Research (INSERM) in Paris, said experiments on mice with HHT have showed thalidomide treatment was able to repair blood vessel wall defects through a mechanism involving proteins involved in cell growth.

"Biopsies of the nasal surface tissue from patients with HHT showed that similar mechanisms may explain the effects of thalidomide treatment in humans,” he wrote in the study.

HHT affects about one in 5,000 people. Many patients develop recurrent, difficult-to-treat nosebleeds which can significantly harm their quality of life.

Thalidomide was used to treat nausea during pregnancy in the 1960s. The drug was taken off the market after severe congenital defects appeared in the newborns of mothers who had taken it.

More recently, thalidomide - which has powerful anti-cancer properties - experienced a revival and is now being used to treat certain forms of cancer such as multiple myeloma.

U.S. drugmaker Celgene has developed a successor drug to thalidomide, called Revlimid, which is also approved to treat multiple myeloma.

SOURCE: Nature Medicine, online April 4, 2010.

RELATED STORIES:
Fat Outside of Arteries May Influence Onset of Coronary Artery Disease   Hard Arteries More Likely with Diabetes   Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines   Losing belly fat, whether from a low-carb or a low-fat diet, helps improve blood vessel function   Stenting for stroke prevention becoming safer in high-risk patients   Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows   Exercise may be better than stents for PAD patients   Protein causes varicose veins   Use of sulodexide in patients with peripheral vascular disease   Scientists discover the proteins that control development of varicose veins   International Consortium Identifies 5 New Genes Affecting The Risk Of Coronary Artery Disease   Study shows soy protein reduced progression of clogged arteries in women within 5 years of menopause

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]